↓ Skip to main content

Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation

Overview of attention for article published in Radiation Oncology, August 2018
Altmetric Badge

Mentioned by

twitter
2 tweeters

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation
Published in
Radiation Oncology, August 2018
DOI 10.1186/s13014-018-1089-8
Pubmed ID
Authors

Hanbo Chen, Jussi Tikkanen, R. Gabriel Boldt, Alexander V. Louie

Abstract

Development of primary lung cancer in donor lung post-lung transplantation is very rare, with few described cases. The safety of stereotactic ablative radiotherapy (SABR) for early-stage lung cancer arising from donor lung is unclear. Herein, we present a case of a patient with a Stage IB adenocarcinoma arising from donor lung 8 years post-double lung transplantation, which was performed due to advanced emphysema. The patient was ineligible for surgical management due to chronic lung allograft dysfunction, which significantly compromised pulmonary function. Full dose SABR was delivered with curative intent after a discussion with the patient. The patient tolerated the treatment well, with one episode of subacute toxicity that resolved with treatment. There was no evidence of recurrence at 15 months post-treatment and the patient's pulmonary function did not deviate from the pre-SABR baseline. SABR appears feasible for medically-inoperable early-stage primary lung adenocarcinoma in the setting of previous double-lung transplantation.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 20%
Professor > Associate Professor 1 20%
Researcher 1 20%
Unknown 2 40%
Readers by discipline Count As %
Medicine and Dentistry 2 40%
Unknown 3 60%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2019.
All research outputs
#11,262,151
of 14,207,392 outputs
Outputs from Radiation Oncology
#1,060
of 1,461 outputs
Outputs of similar age
#204,493
of 274,437 outputs
Outputs of similar age from Radiation Oncology
#1
of 1 outputs
Altmetric has tracked 14,207,392 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,461 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,437 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them